| Similar Articles |
|---|
 |
Bio-IT World
August 18, 2004
Salvatore Salamone |
Interactive Decision Making SurroMed's core goal is to discover and validate new biomarkers for a broad spectrum of diseases.   |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Bio-IT World
Jul/Aug 2006
John Russell |
NCI Awards $1.4M for Biomarker Software The Natonal Cancer Institute has awarded roughly $1.4 million to statistics software specialist Insightful to develop analytic methods and a software suite -- S+ Proteome -- for processing and analyzing protein mass spectra data. |
Bio-IT World
Jul/Aug 2006
Deb Janssen |
Managing the Microarray Data Mountain Genomic studies often involve thousands of samples and require hundreds of thousands of assays per sample. Microarray manufacturers are scurrying to satisfy researcher demands for increased array density, sample number, and content flexibility. |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Bio-IT World
October 10, 2003
Donna Mendrick |
Microarrays That Make Drugs Safe Using DNA chips to discover potential toxicity in new drug compounds -- a key application of toxicogenomics -- can predict adverse effects before they occur, enabling safer clinical trials. |
Bio-IT World
February 2007
Robert M. Frederickson |
Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform. |
Bio-IT World
September 2005
Kristen Amuzzini |
A More Efficient Approach to Biostatistical Data Analysis Using an efficient, integrated approach, data from many different sources can easily be acquired, massaged to ensure its integrity, and then combined into single tables that biostatisticians can use to search for patterns regardless of the source of the data. |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Bio-IT World
March 8, 2005
Patricia Reilly |
Biomarkers: Trends and Potential Companies are centralizing biomarker research to help reduce spending. |
Bio-IT World
August 18, 2004
John Russell |
A Dozen Sparkling Gems A snapshot of deserving Best Practices Awards entries: Locus Pharmaceuticals... Children's Memorial Hospital, Chicago... XOMA... University of Texas Health Science Center... etc. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
Pharmaceutical Executive
January 1, 2006
Clinton & Wechsler |
What Ever Happened to Critical Path FDA's ambitious program to improve drug development disappeared from view almost as soon as it was announced. Suddenly, it's back, but is it here to stay? |
Bio-IT World
September 9, 2002
John P. Helfrich |
Data Management in High-Throughput Screening The high-throughput drug discovery field requires an optimal IT platform. |
Bio-IT World
June 17, 2004
Michael A. Greeley |
A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools. |
Bio-IT World
August 2005 |
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects. |
Bio-IT World
September 2006
Mark D. Uehling |
Spotfire: Seeing Your Clinical Trial Data Jump Spotfire's DecisionSite system offers a new window on clinical research. |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
Bio-IT World
August 13, 2003
Malorye Branca |
Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm. |
Bio-IT World
March 17, 2004
Zachary Zimmerman |
Testing Times for the FDA The FDA's pharmacogenomic guidance marks the beginning of a long process toward standardized tests. |
Bio-IT World
August 13, 2003
John Rhodes |
Beyond the Blockbuster Genomics and big hits are not mutually exclusive, writes Deloitte & Touche's life sciences expert. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
March 10, 2003
Spink & Blumenstiel |
Getting IT Right Applying information technology to trials can boost productivity. Here's a strategic framework for going e-clinical. |
Bio-IT World
October 2006
Kevin Davies |
Microarray Platforms Shine DNA microarrays from the leading commercial sources are more reliably consistent than previously suspected, according to a new study. |
Bio-IT World
August 18, 2004
John Russell |
Curbing a Killer Iconix Pharmaceuticals is working on building biomarkers that can predict toxicity and efficacy. |
Bio-IT World
February 11, 2005
Robert M. Frederickson |
Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use. |
Bio-IT World
March 2006
Kevin Davies |
Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
Bio-IT World
February 18, 2004 |
Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies |
Bio-IT World
January 13, 2003
Julia Boguslavsky |
A Sequel to the Sequence The all-but-complete human genome sequence is not only an indispensable tool for biomedical research but also a major influence on the types of instrumentation researchers will invest in. |
Bio-IT World
September 2006
John A. Wass |
Integrating Knowledge The results of new mathematical routines have the potential to save pharmaceuticals millions of dollars in drug development. And yet the flow of successful drugs is dwindling. The problem goes beyond bureaucracy and lies in the complexity of the problem. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
July 11, 2002
Stephen T.C. Wong |
Neuro-IT Needs Integrated Infrastructure There are two major motivations for merging enterprise solutions into clinical neuroscience. The first is the need to scale up the capacity for data management. The second is the economic benefits of data sharing, software reuse, and infrastructure build-out while reducing costs. |
Wired
August 2003
Jennifer Kahn |
The End of Cancer (As we Know it) Diagnosis. Chemotherapy. Radiation. Slow painful death. No more. A new era of cancer treatment is dawning. Meet three scientists who are using the revelations of the Human Genome Project to reshape medicine. |
Bio-IT World
August 2005
Kevin Davies |
Special Report: Bio-IT World Best Practices 2005 Each year, the Best Practices awards program spotlights examples of the most outstanding innovations, technologies, and practices in the drug discovery pipeline. |
Bio-IT World
February 18, 2004 |
Just Bead It MPSS can help address the limitations of microarrays. |
Bio-IT World
August 2005
Ellen H. Julian |
Tech Expertise Singles Out Outsourcers Biopharmaceutical companies are flocking to consultants, outsourcers, and staffing firms to help with discrete clinical trial processes to gain access to advanced technologies and reduce the drain on already-scarce IT resources. |
Bio-IT World
April 16, 2004 |
Portraits in Proteomics Advances in identifying protein biomarkers are spurring new hope in cancer diagnostics, expediting detection and easing testing. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
November 14, 2003
Jeff Augen |
Making Information-Based Medicine Work A confluence of scientific discovery and high-throughput technology has made information-based medicine possible -- and imperative. |
Information Today
July 2, 2013 |
Thomson Reuters Offers Clinical Trial Intelligence Solutions These solutions improve clinical trials, speed up product development and release, and help professionals strengthen portfolios and R&D strategy. |
Bio-IT World
November 19, 2004
Kevin Davies |
The Book on Bioinformatics Research director David Mount talks about his new book "Bioinformatics: Sequence and Genome Analysis," sequence analysis, and teaching bioinformatics |
Bio-IT World
January 21, 2005
Salvatore Salamone |
A Prescription for Information-Based Medicine TurboWorx president and CEO Jeff Augen not only combines computational and biology expertise, but also has a clear vision of how to advance life science discovery. |
Wired
June 2000
Brian Alexander |
Biopoly Money Patents and strong-arm tactics are helping make Affymetrix the Intel of biochips. Along the way, Affy wants to turn DNA into a proprietary system. |
Bio-IT World
June 17, 2004
Robert M. Frederickson |
Microarray Analysis Reaches the Desktop Various commercial solutions exist to analyze microarray data, from enterprise-level solutions designed primarily for large companies and institute-based support facilities to the more recently emerged desktop solutions for individual research labs. |
Bio-IT World
October 10, 2003
Mel Kronick |
In Situ Chips on Demand Microarray manufacturing technologies are giving new meaning to the term 'custom.' |
Bio-IT World
October 2005
John Russell |
VizXLabs' Incremental Victories How this small informatics software company is succeeding in the mainstreaming of microarrays. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
